Reframe the Paradigm of Hypertension treatment Focus on Diabetes
|
|
- Dylan Banks
- 5 years ago
- Views:
Transcription
1 Reframe the Paradigm of Hypertension treatment Focus on Diabetes Paola Atallah, MD Lecturer of Clinical Medicine SGUMC EDL monthly meeting October 25,2016
2 Overview Physiopathology of hypertension Classification of blood pressure Epidemiology i of hypertension Consequences of hypertension Guidelines for the management of hypertension Antihypertensive drugs ADA Guidelines
3
4
5 Pathophysiology of hypertension
6
7 What is the goal BP?
8
9 Classification of Blood Pressure JNC VII Systolic Diastolic Normal < 120 And < 80 Prehypertension Or Hypertension Stage Or Stage 2 > 160 Or > 100 Highest value (systolic or diastolic) determines Stage
10 High/ Very High Risk Subjects BP 180systolic and/or 110mmHg diastolic SBP >160 mmhg with low DBP (<70 mmhg) DM / MS / 3 CV risk factors Subclinical organ damages: LVH Carotid artery wall thickening or plaque Increased arterial stiffness creatinine GFR or Cr Cl Microalbuminuria or proteinuria Established CV or renal disease
11 Most patients have overlapping CV Risk Factors Overall 23% of individuals without CV comorbidities has HTN Of all dyslipidaemics: 48% have hypertension 14% have type 2 diabetes 35% are overweight/obese HTN was found in: 82% of those with CKD 77% of those with DM 74% in those with PAD 73% of those with CHD Dyslipidaemia 71% in those with CHF 62% in those with MetS 70% in those with stroke 52% in those with dyslipidemia Hypertension Type 2 Diabetes Of all type 2 diabetes: 60% have hypertension 60% have hyperlipidemia 90% are overweight/ obese Wong ND et al. Arch Intern Med 2007;167:2394
12 Hypertension and Diabetes Hypertension is common in type 1 and type 2 diabetes Time course in relation to the duration of diabetes is different In type1: 5% risk at 10y 33%at 20y 70%at 40y In > 3500 newly diagnosed type 2: 39% HTA 50% of them, HTA before the onset of albuminuria Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992; 19:403.
13
14
15 Renal and cardiovascular disease develop in parallel Renal disease CV disease Renal failure ESD Heart failure GFR decline Progression CV events Proteinuria albuminuria Diabetes, HTN ageing Organ damage High risk CHD LVH Diabetes, HTN, ageing
16 Guidelines :HTA management One pill for all??
17
18
19
20
21 Guidelines Acknowledge That Most Patients Need Combination Therapy to Achieve BP Goals JNC 8 Most patients with hypertension will require two or more antihypertensive medications to achieve their BP goals** J When BP is > 20/10 mmhg above goal, consideration should be given to initiating therapy with two drugs 16 ESH 20 NICE Combination treatment should be considered as first choice when there is high CV risk BP is above the hypertension threshold (> 20/10 mmhg), or multiple risk factors, sub clinical organ damage, diabetes, renal or CV disease The use of two or three drugs in combination is often necessary to achieve the target BP control A low dose of a diuretic should be included in this combination The use of two or three drugs in combination is often necessary to achieve the target BP control A low dose of a diuretic should be included din this combination **Chobanian et al. JAMA. 2008;289: ; Mancia et al. Eur Heart J. 2007;28: ; download.aspx?o=cg034fullguideline (accessed January 2010); Ogihara et al. Hypertens Res. 2009;32:3 107.
22 Target Blood Pressure <140/90 mmhg Multipleanti hypertensive agents may be needed to achieve the Multiple anti hypertensive agents may be needed to achieve the desired target
23 Achieving Antihypertensive Goals National Kidney Foundation, Am J Kid Dis 39 (Suppl 1): S1 S321
24 Hypertension in Diabetes (UKPDS) Patients with eve ents (%) Less tight control (mean BP 154/87 mmhg) Tight control (mean BP 144/82 mmhg) Tight BP control: 24% reduction of events (95% CI 8-38) Years from randomization guidelines.diabetes.ca BANTING ( ) diabetes.ca Copyright 2013 Canadian Diabetes Association UKPDS Study Group. BMJ 1998; 317:
25
26 Benefits of BP Lowering in DM Meta analysis of 27 randomized trials showed intense BP reduction (6/4.6 mmhg) resulted in: 36% reduction in stroke 27% reduction in total mortality 25% reduction in major cardiovascular events The important factor was blood pressure reduction not the agent used. Arch Intern Med 2005;165:
27 HOT:BP Control Reduces CV Events Diabetes Subgroup 30 P<0.005 MI, stro oke, CV mortality/ 1000 pt-y Goal of therapy: target diastolic BP 90 mm Hg (n=501) 85 mm Hg g( (n=501) 80 mm Hg (n=499) 5 0 Hansson et al. Lancet. 1998;351:1755.
28 Antihypertensive drugs and diabetes ARB/ACEI may have positive effects on insulin action and plays a role in protecting high risk hypertensive patients from developing diabetes HOPE The development of new diabetes was reduced by 34% (p<0.001) in the Ramipril treated group LIFE Losartan was associated with 25% relative risk reduction in new onset diabetes when compared with ihatenolol l VALUE Valsartan, was associated with 23% RRR in new onset diabetes when compared with amlodipine
29
30 Diuretic - Classes Thiazides Hydrochlorothiazide (HCTZ) 12.5 mg or 25mg Outcome benefits not established Hyponatremia & hypokalemia more common in women >12 combinations with HCTZ available Chlorthalidoneh lid 25 mg provide better 24h hr BP control than HCTZ 50 mg Mg for mg twice as potent as HCTZ Outcome data available regarding reduced CV events
31 Chlorthalidone Reduces Cardiovascular Events
32 Chlorthalidone Reduces Cardiovascular Events
33 Diuretic - Classes Loop If only treating hypertension use only in CKD Potassium sparing Combined with thiazide reduces risk sudden death and hypokalemia Do not combine with continuous K + supplements or in renal failure Increased risk hyperkalemia Especially with ACE or ARB combination
34 Diuretics diabetes, hyperlipidemia? Diuretics can raise glucose & lipid levels short term However, no long term adverse effects in diabetics Fasting glucose increases in older adults regardless antihypertensive drug Diuretics may be safely used in patients with diabetes or hyperlipidemia
35 Best drug for Diabetic patients? The choice of antihypertensive agents in diabetic patients is based upon their ability to prevent adverse cardiovascular events and to slow progression of renal disease, if present The choice is not based upon retinopathy endpoints since p p y p comparative trials have not demonstrated superiority of one agent over another for retinopathy
36 ADA 2016 Guidelines HypertensionManagement: Treatment Targets Measure BP at every visit Confirm elevated BP at separate visit Systolic (SBP) targets <140 mm Hg Lower target (<130 mm Hg) may be appropriate in certain individuals * Screening Treatment targets Diastolic (DBP) targets <90 mm Hg Lower target (<130 mm Hg) may be appropriate in certain individuals * * Younger individuals, those with albuminuria, and/or those with hypertension and one or more additional ASCVD risk factor if lower target can be achieved without undue treatment burden American Diabetes Association. Diabetes Care. 2016;39(suppl 1):S1-S106.
37 ADA 2016 Guidelines Treatment of High Blood Pressure BP>120/80 mm Hg Lifestyle changes Confirmed office BP >140/90 Older adults Pregnant individuals Prompt initiation and timely subsequent titration of pharmacologic therapy in addition to lifestyle changes Treating to <130/70 is not recommended SBP <130 not shown to improve CV outcomes DBP <70 associated with increased mortality Targets of /65 79 recommended to optimize long term maternal health and minimize impaired fetal growth Pharmacologic therapy Regimen to include ACEI or ARB but not both If either class is not tolerated, substitute for the other If using ACEI, ARB, or diuretic, monitor serum creatinine/egfr i and serum potassium levels l ACEI=angiotensin-converting enzyme inhibitor; ARB=angiotensin receptor blocker; egfr=estimated glomerular filtration rate; American Diabetes Association. Diabetes Care. 2016;39(suppl 1):S1-S106.
38 Weight loss DASH style dietary pattern, including: Lifestyle Changes for High Blood Pressure Reduced sodium intake (<2,300 mg/day) Increased potassium intake Increased fruit/vegetable intake (8 10 servings/day) Moderate alcohol intake Increased physical activity ADA 2016 Guidelines DASH=Dietary Approaches to Stop Hypertension American Diabetes Association. Diabetes Care. 2016;39(suppl 1):S1-S106.
39
40
41 Screening Screening and Treatment for Diabetic Kidney Disease ADA 2016 Guidelines Annually measure urinary albumin and egfr in patients with type 1with 5 yr diabetes duration, in all type 2 patients starting at diagnosis, and in all patients with hypertension For individuals with nondialysis dependent diabetic kidney disease: Dietary protein intake should be 0.8 g/kg of body weight per day For individuals on dialysis: Higher levels of protein intake should be considered ACEI or ARB recommended for treatment of nonpregnant individuals with diabetes and modestly elevated urinary albumin excretion ( mg/d) Treatment Strongly recommended d for individuals id with urinary albumin excretion 300 mg/d and/or egfr <60 ml/min/1.73m 2 Periodically monitor serum creatinine and potassium levels when ACEIs, ARBs, or diuretics are used for treatment Monitor urinary albumin-to-creatinine ratio in individuals with albuminuria treated with ACEI or ARB ACEI or ARB not recommended for primary prevention of diabetic kidney disease in individuals with diabetes who have normal BP, urinary albumin-to-creatinine ratio, and egfr ACEI=angiotensin-converting enzyme inhibitor; ARB=angiotensin receptor blocker; egfr=estimated glomerular filtration rate American Diabetes Association. Diabetes Care. 2016;39(suppl 1):S1-S106.
42 Management of for Diabetic Kidney Disease ADA 2016 Guidelines egfr is <60 ml/min/1.73m 2 : evaluate and manage potential complications of chronic kidney disease egfr <30 ml/min/1.73m 2 : refer for evaluation for renal replacement treatment Refer to physician experienced in care of kidney disease for uncertainty about cause of kidneydisease disease, difficultmanagementissues issues, rapidlyprogressingdisease progressing disease egfr egfr egfr <30 Referral to nephrologist if possibility for nondiabetic kidney disease Consider need for dose adjustment of meds Monitor egfr, electrolytes, bicarbonate, calcium, phosphorous, parathyroid hormone, hemoglobin, albumin, weight every 6 months Assure vitamin D sufficiency Consider bone density testing Refer for dietary counseling Monitor egfr every 3 months Monitor electrolytes, bicarbonate, calcium, phosphorous, parathyroid hormone, hemoglobin, albumin, weight every 3 months Consider needfor dose adjustment of meds Refer to a nephrologist egfr=estimated glomerular filtration rate American Diabetes Association. Diabetes Care. 2016;39(suppl 1):S1-S106.
43 ADA 2016 Guidelines Screening Treatment Children and Adolescents WithType 1 Diabetes: High Blood Pressure Measure BP at every visit Confirm elevated BP at separate visit High normal BP * or hypertension : confirm BP on 3 separate days High normal BP * Lifestyle changes (diet & physical activity) aimed at weight control Initial pharmacologic If target BP not achieved within 3 6 months, therapy: initiate pharmacologic therapy ACEI or ARB (Never in Hypertension combination) Initiate lifestyle changes and pharmacologic therapy Target: Consistently <90th percentile for age, gender, and height * SBP or DBP consistently 90th percentile for age,, and height SBP or DBP consistently 95th percentile for age, gender, and height Provide counseling regarding potential teratogenic effects Not all ACEIs and ARBs are indicated for use in children/adolescents by the U.S. Food and Drug Administration (FDA). Refer to full prescribing information for indications and uses in pediatric populations. American Diabetes Association. Diabetes Care. 2016;39(suppl 1):S1-S106.
44 ADA 2016 Guidelines Managing ghypertension During Pregnancy BP is lower during a normal pregnancy than in the nonpregnant state Target BP for pregnancy complicated by diabetes Antihypertensive medications Safe medications Methyldopa Labetalol Diltiazem Clonidine Prazosin SBP: mm Hg DBP: mm Hg Unsafe medications (contraindicated) ACEIs ARBs ACEI=angiotensin-converting enzyme inhibitor; ARB=angiotensin receptor blocker; DBP=diastolic blood pressure; SBP=systolic blood pressure American Diabetes Association. Diabetes Care. 2016;39(suppl 1):S1-S106.
45 Conclusions HTA occurs in 75% of patients t with type 2 diabetes is common in type 1 diabetes HTA is a promoter of macro and micro vascular disease There is evidence to link the RAAS with hypertension in yp patients with obesity, metabolic syndrome, and type 2 diabetes
46 Summary of Pharmacotherapy for Hypertension in Patients with Diabetes Threshold equal or over 140/90 mmhg and Target below 140/90 mmhg Diabetes With Nephropathy, CVD or CV risk factors Without the above ACE Inhibitor or ARB 1. ACE Inhibitor or ARB or 2. Thiazide diuretic or DHP-CCB Combination of 2 first line drugs may be considered as initial therapy if the blood pressure is >20 mmhg systolic or >10 mmhg diastolic above target > 2-drug combinations Monitor serum potassium and creatinine carefully in patients with CKD prescribed an ACEI or ARB More than 3 drugs may be needed to reach target values If Creatinine over 150 µmol/l or creatinine clearance below 30 ml/min ( 0.5 ml/sec), a loop diuretic should be substituted for a thiazide diuretic if control of volume is desired
47 We are still evolving towards finding an Ideal Antihypertensive
Diabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationHypertension Update. Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy
Hypertension Update Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy Introduction 1/3 of US adults have HTN More prevalent in non-hispanic
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationManaging Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park.
Managing Hypertension in Diabetes 2015 Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park Case Scenario Mike M is a 59 year old man with type 2 diabetes managed
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationManagement of Hypertension. Ahmed El Hawary MD Suez Canal University
Management of Hypertension Ahmed El Hawary MD Suez Canal University Minimal vs. Optimal Care Resources more than science affect type of care and level of management. what is possible (minimal care) and
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationNew Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationModern Management of Hypertension
Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence
More informationHypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg
Hypertension diagnosis (see detail document) Non-diabetic Diabetic Very elderly (older than 80 years) Target less than 140/90mmHg Target less than 130/80mmHg Consider SBP target less than 150mmHg Non-diabetic
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More informationMODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationHypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
More informationDifficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition ACOFP - The Heart of the Matter - An Evidence
More informationCombination Therapy for Hypertension
Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP
More informationNew Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets
New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of
More informationWhich antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017
Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017 The most important reason for treating hypertension in primary care is to prevent
More informationModern Management of Hypertension: Where Do We Draw the Line?
Modern Management of Hypertension: Where Do We Draw the Line? Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Blood Pressure
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationMANAGEMENT OF HYPERTENSION IN PREGNANCY, THE ALGORHITHM
MANAGEMENT OF HYPERTENSION IN PREGNANCY, THE ALGORHITHM Are Particular Anti-hypertensives More Effective or Harmful Than Others in Hypertension in Pregnancy? Existing data is inadequate Methyldopa and
More information7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension
Prevalence of Hypertension Hypertension: Diagnosis and Management T. Villela, M.D. Program Director University of California, San Francisco-San Francisco General Hospital Family and Community Medicine
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES
Specific effects of calcium channel blockers in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Non-dihydropyridine calcium channel
More informationManaging Hypertension in 2016
Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour
ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour Dr Indranil Dasgupta Rationale No national practical
More informationSystolic Blood Pressure Intervention Trial (SPRINT)
09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP
More informationKidney Disease, Hypertension and Cardiovascular Risk
1 Kidney Disease, Hypertension and Cardiovascular Risk George Bakris, MD, FAHA, FASN Professor of Medicine Director, Hypertensive Diseases Unit The University of Chicago-Pritzker School of Medicine Chicago,
More informationChronic Kidney Disease
Chronic Kidney Disease Chronic Kidney Disease (CKD) Educational Objectives Outline Demographics Propose Strategies to slow progression and improve outcomes Plan for treatment of CKD Chronic Kidney Disease
More informationHypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD?
Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD? Suzanne Oparil, MD Distinguished Professor of Medicine, Professor of Cell, Developmental and Integrative Biology Director, Vascular
More informationALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationHypertension in the Era of ACC/AHA: Practice Changing Evidence and Recommendations
Hypertension in the Era of ACC/AHA: Practice Changing Evidence and Recommendations Gerald W. Smetana, M.D., MACP Division of General Medicine Beth Israel Deaconess Medical Center Professor of Medicine
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationUsing the New Hypertension Guidelines
Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in
More informationHypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015
Hypertension Update Beverly J. Mathis, D.O. OOA May 2015 Objectives Learn new recommendations for BP treatment goals Approach to hypertension in the office Use of hypertensive drugs, and how to tailor
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES
ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level
More informationInt. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences
Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,
More informationManagement of Hypertension in Women
Management of Hypertension in Women Eliseo J. Pérez-Stable MD Professor of Medicine DGIM, Department of Medicine July 1, 2013 Declaration of full disclosure: No conflict of interest (I have never been
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationClinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More informationHypertensionTreatment Guidelines. Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC
HypertensionTreatment Guidelines Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC Objectives: Review the definition of the different stages of HTN. Review the current guidelines for treatment of HTN. Provided
More informationVA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease in Primary Care (2008) PROVIDER REFERENCE CARDS Chronic Kidney Disease
VA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease in Primary Care (2008) PROVIDER REFERECE CARDS Chronic Kidney Disease CKD VA/DoD Clinical Practice Guideline for the Management
More informationManagement of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine
Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing
More informationManagement of High Blood Pressure in Adults
Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) James, P. A. (2014, February 05). 2014 Guideline for Management
More informationNew Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD
New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD None Disclosures Objectives Understand trend in blood pressure clinical practice guidelines
More informationDEPARTMENT OF GENERAL MEDICINE WELCOMES
DEPARTMENT OF GENERAL MEDICINE WELCOMES 1 Dr.Mohamed Omar Shariff, 2 nd Year Post Graduate, Department of General Medicine. DR.B.R.Ambedkar Medical College & Hospital. 2 INTRODUCTION Leading cause of global
More informationHypertension Management: A Moving Target
9:45 :30am Hypertension Management: A Moving Target SPEAKER Karol Watson, MD, PhD, FACC Presenter Disclosure Information The following relationships exist related to this presentation: Karol E. Watson,
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationAdult Blood Pressure Clinician Guide June 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Blood Pressure Clinician Guide June 2018 Adult Blood Pressure Clinician Guide June 2018 Introduction This Clinician Guide is based on the 2018
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationWe are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients.
Richard Roetzheim, MD, MSPH is Professor and Chair, Department of Family Medicine at the University of South Florida Morsani College of Medicine. Dr. Roetzheim has considerable experience leading NIH funded
More informationUpdate on Current Trends in Hypertension Management
Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student
More informationDisclosures. Learning Objectives. Hypertension: a sprint to the finish Ontario Pharmacists Association 1
Disclosures I have no current or past relationships with commercial entities I have received a speaker s fee from the Ontario Pharmacists Association for this learning activity Laura Tsang PharmD Sunnybrook
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationUpdate in Cardiology Pharmacologic Management of Cardiovascular Risk. Christopher C. Roe, MSN, ACNP
Update in Cardiology Pharmacologic Management of Cardiovascular Risk Christopher C. Roe, MSN, ACNP Objectives 1. Verbalize understanding of new pharmacologic guidelines in the treatment of hypertension
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationLessons learned from AASK (African-American Study of Kidney Disease and Hypertension)
Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension) Janice P. Lea, MD, MSc, FASN Professor of Medicine Chief Medical Director of Emory Dialysis ASH Clinical Specialist
More informationALLHAT. ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status
ALLHAT Antihypertensive Trial Results by Baseline Diabetic & Fasting Glucose Status 1 Introduction and Background Clinical trials have reported reduction in CV events with diuretics, CCBs, ACE inhibitors,
More informationDifficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair
Difficult-to-Control & Resistant Hypertension Anthony Viera, MD, MPH, FAHA Professor and Chair Objectives Define resistant hypertension Discuss evaluation strategy for patient with HTN that appears difficult
More informationTread Carefully Because you Tread on my Nephrons. Prescribing Hints in Renal Disease
Tread Carefully Because you Tread on my Nephrons Prescribing Hints in Renal Disease David WP Lappin,, MB PhD FRCPI Clinical Lecturer in Medicine and Consultant Nephrologist and General Physician, Merlin
More informationHypertension 2015: Recent Evidence that Will Change Your Practice
Hypertension 2015: Recent Evidence that Will Change Your Practice Gerald W. Smetana, M.D. Division of General Medicine Beth Israel Deaconess Medical Center Professor of Medicine Harvard Medical School
More informationThe New Hypertension Guidelines
The New Hypertension Guidelines Joseph Saseen, PharmD Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Disclosure Joseph Saseen reports no conflicts
More informationBlood Pressure Treatment Goals
Blood Pressure Treatment Goals Kenneth Izuora, MD, MBA, FACE Associate Professor UNLV School of Medicine November 18, 2017 Learning Objectives Discuss the recent studies on treating hypertension Review
More informationΣτόχοι αρτηριακής πίεσης σε ειδικούς πληθυσµούς και επιλογή φαρµάκων
Στόχοι αρτηριακής πίεσης σε ειδικούς πληθυσµούς και επιλογή φαρµάκων Εύα Καρπάνου Δ/ντρια Αντιυπερτασικού Ιατρείου Α ΚΚ Ωνάσειου ΚΚ Θεσσαλονίκη, 14/2/13 Η µελέτη δεν υποστηρίχθηκε από φαρµακευτικές εταιρείες
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationEgyptian Hypertension Guidelines
Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich
More informationUpdates in Cardiovascular Recommendations for Diabetic Patients
Updates in Cardiovascular Recommendations for Diabetic Patients Chris Tawwater, Pharm.D., BCPS Clinical Pharmacist, Abilene Regional Medical Center Assistant Professor, Adult Medicine Division Pharmacotherapy
More informationDr Doris M. W Kinuthia
Dr Doris M. W Kinuthia Objectives Normal blood pressures in children Measurement of blood pressure in children Aetiology of Hypertension in children Evaluation of children with hypertension Treatment of
More informationQUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
More informationHypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital
Hypertension and obesity Dr Wilson Sugut Moi teaching and referral hospital No conflict of interests to declare Obesity Definition: excessive weight that may impair health BMI Categories Underweight BMI
More informationHypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
More informationNew Treatment Options for Diabetic Nephropathy patients. Prof. M. Burnier, Service of Nephrology and Hypertension CHUV, Lausanne, Switzerland
New Treatment Options for Diabetic Nephropathy patients Prof. M. Burnier, Service of Nephrology and Hypertension CHUV, Lausanne, Switzerland Diabetes and nephropathy Diabetic nephropathy is the most common
More informationReducing proteinuria
Date written: May 2005 Final submission: October 2005 Author: Adrian Gillin Reducing proteinuria GUIDELINES a. The beneficial effect of treatment regimens that include angiotensinconverting enzyme inhibitors
More informationPrevention of Heart Failure: What s New with Hypertension
Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults
More informationDiabetic Nephropathy. Objectives:
There are, in truth, no specialties in medicine, since to know fully many of the most important diseases a man must be familiar with their manifestations in many organs. William Osler 1894. Objectives:
More informationStages of Chronic Kidney Disease (CKD)
Early Treatment is the Key Stages of Chronic Kidney Disease (CKD) Stage Description GFR (ml/min/1.73 m 2 ) >90 1 Kidney damage with normal or GFR 2 Mild decrease in GFR 60-89 3 Moderate decrease in GFR
More informationHypertension in Geriatrics. Dr. Allen Liu Consultant Nephrologist 10 September 2016
Hypertension in Geriatrics Dr. Allen Liu Consultant Nephrologist 10 September 2016 Annual mortality (%) Cardiovascular Mortality Rates are Higher among Dialysis Patients 100 10 1 0.1 0.01 0.001 25-34
More informationHYPERTENSION: ARE WE GOING TOO LOW?
HYPERTENSION: ARE WE GOING TOO LOW? George L. Bakris, M.D.,F.A.S.N.,F.A.S.H., F.A.H.A. Professor of Medicine Director, ASH Comprehensive Hypertension Center University of Chicago Medicine Chicago, IL USA
More informationTreating Hypertension in 2018: What Makes the Most Sense Today?
Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or
More information